Abstract:Tumor suppressor BRCA2 functions in multiple pathways. The role of BRCA2 in homologous recombination, also termed homology-directed repair (HDR), is particularly well known. We also showed that it has a key role in the protection of stalled replication forks from the MRE11 nuclease. Moreover, BRCA2 also suppresses the formation of single-stranded gaps during replication. We have attempted to delineate the relative contributions of these three pathways to the maintenance of genome integrity and chemotherapy response using separation of function alleles. First, we report that mouse and human cells require a RAD51 filament stabilization motif in BRCA2 for both fork protection and gap suppression but not HDR. In mice, loss of fork protection and gap suppression do not compromise genome instability or shorten tumor latency. By contrast, HDR deficiency increases spontaneous and replication stress-induced chromosome aberrations and tumor predisposition. Unlike with HDR, fork protection and gap suppression defects are also observed in Brca2 heterozygous cells from mice, likely due to reduced RAD51 stabilization at stalled forks and gaps. Sensitivity to the PARP inhibitor olaparib is greatest for HDR-deficient cells, although fork protection/gap suppression-defective cells show a weak sensitivity. Gaps arise from PRIMPOL activity, which is associated with sensitivity to 5-hydroxymethyl-2'-deoxyuridine (hmdU) and DNPH1 inhibition due to the formation of SMUG1-generated abasic sites and is exacerbated by poly(ADP-ribose) polymerase inhibition. In summary, this work demonstrates that HDR deficiency has the major role in generating sensitivity to chemotherapeutics, although gap suppression deficiency may be targeted by specific agents. Citation Format: Pei Xin Lim, Maria Jasin. BRCA2 promotes genomic integrity and therapy resistance primarily through its role in homology-directed repair [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: DNA Damage Repair: From Basic Science to Future Clinical Application; 2024 Jan 9-11; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2024;84(1 Suppl) nr IA014.

BRCA1-associated Complexes: New Targets to Overcome Breast Cancer Radiation Resistance

Brca1-Associated Proteins: Novel Targets For Breast Cancer Radiation Therapy

Targeting Bromodomain Protein ANCCA/ATAD2 Enhances the Efficacy of DNA‑damaging Chemotherapy Agents and Radiation.

Targeting the DNA Repair Pathway for Breast Cancer Therapy: Beyond the Molecular Subtypes.

Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.

Molecular Functions of BRCA1 in the DNA Damage Response

BRCA mutations in the manifestation and treatment of ovarian cancer.

BRCA1 and BRCA2 in Breast Cancer Predisposition and Recombination Control

RAP80-directed Tuning of BRCA1 Homologous Recombination Function at Ionizing Radiation-Induced Nuclear Foci.

Brcc36 is Essential for Ionizing Radiation-Induced Brca1 Phosphorylation and Nuclear Foci Formation

Pharmacological inhibition of BAP1 recruits HERC2 to competitively dissociate BRCA1–BARD1, suppresses DNA repair and sensitizes CRC to radiotherapy

BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies

Innovative therapeutic strategies to overcome radioresistance in breast cancer

Targeting BRCA‐mutant Biliary Tract Cancer: Current Evidence and Future Perspectives

The antitumorigenic roles of BRCA1–BARD1 in DNA repair and replication

DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer

Abstract IA014: BRCA2 promotes genomic integrity and therapy resistance primarily through its role in homology-directed repair

Preclinical Evaluation of Radiation Therapy of BRCA1-associated Mammary Tumors Using a Mouse Model

Phosphorylation of BRCA1 at serine 1387 plays a critical role in cathepsin S-mediated radiation resistance via BRCA1 degradation and BCL2 stabilization

The Role of BRCA1 in DNA Damage Response

Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer